

Physiomics Plc
The Magdalen Centre
The Oxford Science Park
Robert Robinson Avenue
Oxford
OX4 4GA
UK

16th April 2018

Physiomics Plc

("Physiomics" or "the Company")

Physiomics to Present at BioTrinity 2018



Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it will attend BioTrinity 2018. BioTrinity is one of Europe's leading biopartnering and investment conferences, to be held on 23-25 April at the Novotel London West.

In addition to participating in a number of partnering meetings, Dr Jim Millen, CEO, will present a company update at 12.25pm on Tuesday 24th April.

Founded and produced by OBN, BioTrinity is now in its 12th year. BioTrinity continues to grow with more than 1000 senior executives and decision makers from emerging and established companies across the life sciences sector are expected to attend.

For further information please contact:

Physiomics Plc
Dr Jim Millen
+44 (0)1865 784980

WH Ireland Limited (nomad)
Katy Mitchell
+44 (0) 161 832 2174

Hybridan LLP (broker)

Claire Louise Noyce
+44 (0) 203 764 2341

About Physiomics plc

Physiomics plc (AIM: PYC) is a solutions provider to the R&D-based pharmaceutical and biotechnology industry with a focus on oncology. The Company's Virtual Tumour technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Virtual Tumour has been confirmed by 55 projects, involving over 25 targets and 60 drugs.

Based in Oxford, UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

Physiomics' senior management has academic and commercial expertise, including over 90 years collectively of working in oncology and/or computational biology and over 100 publications in peer reviewed journals.